Clinical Trial Update: Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of tislelizumab with chemoradiotherapy for esophageal squamous cell carcinoma; the study is active but not cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING